24/7 Wall St. » GHDX

Top Analyst Upgrades & Downgrades (ADBE, EMR, HEV, FNSR, GHDX, KMI, KMP, KMR, MU, OC, SCHS, SBUX, SWC, TCT, TWGP)

Administrator — Wed, 23 Mar 2011 12:22:13 +0000

These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Wednesday morning.

Adobe Systems Inc. (NASDAQ: ADBE) Maintained Neutral but cut estimates at Credit Suisse.
Emerson Electric Co. (NYSE: EMR) Reiterated Buy with $70 target at BofA/ML.
Ener1, Inc. (NASDAQ: HEV) Reiterated Buy and $5 target at BofA/ML.
Finisar Corporation (NASDAQ: FNSR) Maintained Outperform and $29 target at Credit Suisse.
Genomic Health Inc. (NASDAQ: GHDX) Cut to Neutral at Piper Jaffray.
Kinder Morgan, Inc. (NYSE: KMI) Started as Neutral with $32 target at BofA/ML; Started as Neutral with $32 target at Credit Suisse.
Kinder Morgan Energy Partners LP (NYSE: KMP) Resumed as Buy at BofA/ML.
Kinder Morgan Management LLC (NYSE: KMR) Resumed as Buy at BofA/ML.
Micron Technology Inc. (NASDAQ: MU) Maintained Outperform but cut estimates at Credit Suisse.
Owens Corning Inc. (NYSE: OC) Raised to Buy at BofA/ML.
School Specialty, Inc. (NASDAQ: SCHS) Maintained Outperform as Bull of the Day at Zacks.
Starbucks Corporation (NASDAQ: SBUX) Reiterated Buy and Raised target to $42 at Argus.
Stillwater Mining Company (NYSE: SWC)
Textron Inc. (NYSE: TXT) Raised to Overweight at JPMorgan.
Tower Group, Inc. (NASDAQ: TWGP) Cut to Underperform as Bear of the Day at Zacks.

You can join our free daily email distribution list to hear more about analyst upgrades and downgrades, top day trader and active trader alerts, dividend trends, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Filed under: Analyst Calls Tagged: ADBE, EMR, FNSR, GHDX, HEV, KMI, KMP, KMR, MU, OC, SBUX, SCHS, SWC, TCT, TWGP

The Month’s Biggest Index Losers: Chinese Agriculture, Genetic Analysis, and Agricultural Chemical And Fertilizer Stocks

247wallst — Fri, 23 Apr 2010 17:03:07 +0000

There were strong losses in three Tickerspy indexes over the most recent 30-day period. This month’s biggest losers are in Chinese agriculture, genetic analysis, and agricultural chemical and fertilizer stocks.

Chinese agriculture stocks are down 10.2% in the past month. The worst performing stocks in the index are China Agritech Inc., (NASDAQ: CAGC) down 24.6%%, China Organic Agriculture, Inc., (OTC: CNOA) down 17.5%%, and China Green Agriculture, Inc., (NYSE: CGA) down 6.5%.

Chart and ticker information after the jump.

Genetic analysis stocks are down 8.0% in the past month. The worst performing stocks in the index are Exact Sciences Corporation, (NASDAQ: EXAS) down 12.4%, Clinical Data, Inc., (NASDAQ: CLDA) down 11.6%, and Genomic Health Inc. (NASDAQ: GHDX) down 11.3%.

Chart and ticker information after the jump.

Agricultural and chemical fertilizer stocks are down 7.0% in the past month. The worst performing stocks in the index are China Agritech Inc., (NASDAQ: CAGC) down 24.6%, Intrepid Potash, Inc., (NYSE: IPI) down 13.7%, and Agrium Inc., (NYSE: AGU) down 12.0%.

Chart and ticker information after the jump.

-24/7 Wall St.

Filed under: Research Tagged: AGU, CGA, CLDA, CNOA, EXAS, GAGC, GHDX, IPI

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

247wallst — Wed, 27 May 2009 18:34:32 +0000

We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend. This is broken down in drug and biotech companies with share values, ranges, and recent developments for the following drug and biotech companies: Abraxis BioScience, Inc. (NASDAQ:ABII), AEterna Zentaris Inc. (NASDAQ: AEZS), Allos Therapeutics, Inc. (NASDAQ: ALTH), Amgen Inc. (NASDAQ: AMGN), A.P. Pharma, Inc. (Nasdaq: APPA), Arqule Inc. (NASDAQ: ARQL), Bristol-Myers Squibb (NYSE: BMY), Celldex Therapeutics (NASDAQ: CLDX), Celgene Corporation (NASDAQ: CELG), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), Micromet, Inc. (NASDAQ: MITI), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Rosetta Genomics (NASDAQ:ROSG), Synta Pharmaceuticals (NASDAQ: SNTA), Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), ZIOPHARM Oncology (NASDAQ: ZIOP), and ZymoGenetics, Inc. (NASDAQ: ZGEN).

The full presentation can be seen at BioHealthInvestor.com.

JON C. OGG
May 27, 2009

Posted in Biotech, Drug companies, FDA, Medical, Pharmaceuticals Tagged: ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CELG, CGRB, CLDX, CTIC, EXEL, GHDX, GSK, IMGN, LLY, MDVN, MEDX, MITI, OGXI, OSIP, PFE, PPHM, ROSG, SNTA, TRBN, ZGEN, ZIOP

Previewing 2009 ASCO Abstracts (ABII, ALTH, ARQL, CLDX, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, OGXI, OSIP, PPHM, PFE, SNTA, ZIOP)

247wallst — Thu, 14 May 2009 21:56:52 +0000

We are just about to get the first round of abstracts from companies presenting data at this year’s American Society of Clinical Oncology meeting for 2009. At BioHealthInvestor.com we compiled a brief summary for companies such as Abraxis BioScience, Inc. (NASDAQ:ABII), Allos Therapeutics, Inc. (NASDAQ: ALTH), Arqule Inc. (NASDAQ: ARQL), Celldex Therapeutics (NASDAQ: CLDX), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Synta Pharmaceuticals (NASDAQ: SNTA), and ZIOPHARM Oncology (NASDAQ: ZIOP).

You can see that full pre-report here at BiohealthInvestor.com. As always be advised that there may be new sets of data released between now and the actual meeting from May 29 to June 2, 2009 in Orlando, Florida.

Posted in Biotech, Drug companies, Medical, Pharmaceuticals Tagged: ABII, ALTH, ARQL, CGRB, CLDX, CTIC, EXEL, GHDX, GSK, IMGN, LLY, MDVN, MEDX, OGXI, OSIP, PFE, PPHM, SNTA, ZIOP

Top 10 Pre-Market Analyst Calls (DVR, GHDX, KLAC, KR, LCAPA, LOW, NOK, PBT, TMA, UBS)

247wallst — Wed, 12 Mar 2008 06:51:31 +0000

Below are the top calls that 247WallSt.com is focusing on in pre-market trading this Wednesday:

Cal Dive International (NYSE: DVR) Raised To Overweight at JP Morgan.
Genomic Health (NASDAQ: GHDX) Cut To Neutral at JP Morgan.
KLA-Tencor (NASDAQ: KLAC) cut to Underperform at Oppenheimer.
Kroger (NYSE: KR) cut to Underweight at at JPMorgan.
Liberty Capital (NASDAQ: LCAPA) cut to Hold at Deutsche Bank.
Lowe’s (NYSE: LOW) cut to Underperform at Morgan Keegan.
Nokia (NYSE: NOK) raised to Outperform at Oppenheimer.
Permian Basin (NYSE: PBT) cut to Hold at Citigroup.
Thornburg Mortgage (NYSE: TMA) Raised to Peer Perform at Bear Stearns.
UBS (NYSE: UBS) cut to Underperform at KBW.

Jon C. Ogg
March 12, 2008